Skip to main content
logo
Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
1.870
+0.010 (0.54%)
At close: Oct 9, 2026, 4:00 PM EDT
1.861
-0.010 (-0.51%)
After-hours: Oct 9, 2026, 7:30 PM EDT

Tenax Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
23.3623.716.795.015.686.38
Research & Development
45.2632.6712.713.235.3825.15
Operating Expenses
68.6156.3919.498.2311.0531.53
Operating Income
-68.61-56.39-19.49-8.23-11.05-31.53
Interest Expense
---0.02-0.02-0-0
Interest & Investment Income
3.783.821.910.48--
Other Non Operating Income (Expenses)
-0.03-0.0300.060.010.02
EBT Excluding Unusual Items
-64.86-52.6-17.6-7.71-11.05-31.51
Gain (Loss) on Sale of Investments
------0.01
Gain (Loss) on Sale of Assets
----0-
Other Unusual Items
------0.95
Pretax Income
-64.86-52.6-17.6-7.71-11.05-32.47
Net Income
-64.86-52.6-17.6-7.71-11.05-32.47
Net Income to Common
-64.86-52.6-17.6-7.71-11.05-32.47
Net Income Growth
------
Shares Outstanding (Basic)
443915000
Shares Outstanding (Diluted)
443915000
Shares Change
31.87%156.80%6046.87%1250.92%43.00%-
EPS (Basic)
-1.47-1.34-1.15-31.04-600.72-2525.03
EPS (Diluted)
-1.47-1.34-1.15-31.04-600.72-2525.03
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-46.03-35.8-14.81-5.9-11.39-10.86
Free Cash Flow Per Share
-1.04-0.91-0.97-23.76-619.37-844.53
EBITDA
---19.49-8.23-11.05-31.52
D&A For EBITDA
--0.010.010.010
EBIT
-68.61-56.39-19.49-8.23-11.05-31.53
SEC Filings: 10-K · 10-Q